Blackmores Hyperiforte

Quick links to important sections

Blackmores Hyperiforte

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blackmores Hyperiforte

Quick Facts

Property Description
Active Ingredient Hypericum perforatum (St John's Wort) extract
Form Film-coated tablet
Pharmacological Class Herbal Antidepressive Agent / Neurotonic
Common Use Supporting healthy mood balance
Origin Natural (Botanical)

What Type of Preparation is Blackmores Hyperiforte?

Blackmores Hyperiforte is an oral, single-ingredient, herbal medicine presented as a film-coated tablet for convenient ingestion. Its classification places it among neurotonic and antidepressive agents suitable for managing mild mood disturbances. The active substance is derived from the St John's Wort plant (Hypericum perforatum), a component traditionally valued in Western herbal medicine. Within the scope of botanical medicinal products, Hypericum perforatum is utilized for the management of mild to moderate depressive symptoms. Its over-the-counter status makes it accessible to individuals seeking a natural intervention to manage emotional well-being without a prescription.

Composition: Why Standardised St John's Wort Extract is Key

The product's efficacy is contingent upon a standardised, dry, concentrated extract of Hypericum perforatum. This standardization process ensures a reliable concentration of the herb's therapeutic compounds, notably the naphthodianthrones (like hypericin) and phloroglucinols (like hyperforin). The use of a standardized extract is intended to provide predictable therapeutic outcomes, distinguishing this formulation from general herbal supplements with variable potency. This commitment to quality ensures a dedicated, single-agent preparation for nervous system support.

General Purpose: What Does Blackmores Hyperiforte Help to Relieve?

The primary therapeutic purpose of Blackmores Hyperiforte is to support healthy mood balance and assist the nervous system in dealing with periods of stress. Its action involves modulating neurotransmitter activity within the central nervous system. This function is typically employed to help individuals maintain a stable emotional state and cope with nervous tension and mild anxiety associated with everyday demands. Its benefit centers on stabilizing the nervous system and promoting a greater sense of emotional equilibrium.

Regulatory References

  1. NCBI/NIH St. John's Wort Review

What side effects are possible with Blackmores Hyperiforte?

Possible Side Effects and Safety Information

The official safety profile for preparations containing Hypericum perforatum extract (St John’s Wort) is characterized by documented adverse reactions, specific population constraints, and significant drug-interaction risks, which are a critical safety concern noted in regulatory documents.

Adverse Reaction Scope

Category Regulatory Documentation Status
Frequency Classification Most reported effects, such as gastrointestinal disturbances, fatigue, and allergic skin reactions, are officially classified as Frequency Not Known as they cannot be estimated from available data.
System-Organ Classes Involved Gastrointestinal disorders, Skin and subcutaneous tissue disorders, Nervous system disorders (e.g., headaches, dizziness), and Psychiatric disorders (e.g., restlessness, anxiety, mania) are systems associated with reported reactions.

Serious Safety Consequences and Constraints

The most serious safety concerns documented in regulatory sources relate to drug interactions and specific exposure risks:

  • Serious Drug Interaction Consequences: A significant risk is the loss of therapeutic effect for many critical co-administered medicines, including oral contraceptives, HIV medication, and anticoagulants. This effect can lead to severe adverse outcomes like therapeutic failure or unintended pregnancy. Increased incidence of serotonin-related adverse reactions (Serotonin Syndrome risk) is also noted when this preparation is used alongside other serotonergic agents.
  • Photosensitivity Risk: The preparation is associated with intensified sunburn-like symptoms (photosensitisation), particularly in fair-skinned individuals exposed to strong sunlight or UV irradiation. Official safety constraints mandate that intense UV exposure (sunbeds, sunbathing) must be avoided during treatment.
  • Population and Use Constraints: Use is not recommended in children under 12 or during pregnancy and lactation due to the absence of sufficient safety data. The preparation should also be discontinued at least 10 days prior to elective surgery to avoid potential interaction risks with anaesthetics.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

Feature Official Regulatory Statement/Entity
Documented Manifestations: Seizures and confusion have been reported following the ingestion of massive overdoses of the extract.
Physiological Systems Affected: Central Nervous System and the skin (Photosensitization risk).
Exposure Factor: Symptoms are associated with the intake of massive overdoses of the preparation.
Emergency Action Threshold: The presence of severe symptoms such as passing out or trouble breathing mandates an urgent call to emergency services.

Overdose Management and Required Action

The official overdose profile requires the immediate notification of emergency services. In the presence of serious or life-threatening symptoms, the guidance is to seek immediate medical attention and contact a poison control center right away.

A specific procedural instruction following a massive overdose is the requirement for the patient to be protected from direct sunlight and other ultraviolet (UV)-light sources for one to two weeks. This is due to the documented phototoxicity risk of the active ingredient. Treatment for overdose is generally described in regulatory documents as symptomatic and supportive. There is no specific antidote listed for this overdose.

The risk of a severe outcome, such as Serotonin Syndrome, is a critical consideration in overdose, particularly if the preparation is combined with other serotonergic medicines.

Therapeutic Uses of Blackmores Hyperiforte

The therapeutic application of Blackmores Hyperiforte focuses on providing supportive relief for emotional well-being, targeting symptomatic domains associated with non-severe mood distress and symptoms related to systemic imbalance.

Mood Balance and Mild Depressive Support

This preparation is commonly used for addressing mild to moderate depressive episodes and associated low mood. It is intended to promote a healthy mood balance, contribute to improved comfort during periods of heightened symptoms, and support the maintenance of functional stability.

The primary symptomatic focus generally includes low mood, nervous tension, and patterns of disrupted emotional equilibrium.

Relief of Nervous Tension and Restlessness

The preparation is relevant for managing symptom clusters characterized by nervous tension and inner restlessness. It offers supportive relief for symptoms related to heightened physiological activity, generally used during phases of increased distress or discomfort. This is applied when symptoms create noticeable functional strain and helps individuals cope more steadily with challenging symptomatic phases.

Therapeutic Focus: Nervous Tension Support
Primary Benefit Helps support emotional equilibrium.
Symptom Focus Inner restlessness and general agitation.
Context of Use During phases of increased emotional distress.

Regulatory References

  1. Health Canada Natural Health Product Monograph on St. John's Wort

Eligibility and Restrictions for Use

The eligibility for Blackmores Hyperiforte, a preparation containing Hypericum perforatum (St John's Wort) extract, is strictly defined by official regulatory documentation and is not advised for several patient groups.

Eligibility Status Patient Population Regulatory Basis
Use Allowed Adults and the Elderly Use is established for the approved indications.
Not Recommended Children and adolescents under 18 years of age Data are insufficient to establish safety and efficacy.
Not Recommended Pregnant or Breastfeeding women Precautionary restriction due to a lack of conclusive safety data.
Contraindicated Individuals with known hypersensitivity to the extract Absolute non-eligibility rule (e.g., EMA Monograph).
Contraindicated Patients with severe depressive episodes Product is indicated only for mild to moderate low mood.
Contraindicated Patients with known dermal photosensitivity Risk of severe sunburn-type reactions due to photosensitization.
Contraindicated Patients on specific concurrent, critical medicines Includes transplant patients on immunosuppressants and HIV patients on antiretrovirals.

Eligibility is constrained to adult users treating mild-to-moderate symptoms. The official profile explicitly prohibits use in specific populations defined by treatment status or inherent conditions, such as dermal photosensitivity or use of critical, narrow therapeutic index drugs.

What should I know about interactions with other medicines?

Blackmores Hyperiforte, containing Hypericum perforatum (St John's Wort) extract, has an officially documented and clinically significant interaction potential with a wide range of prescription medicinal products. The primary interaction is classified as pharmacokinetic, based on the extract's role as a potent inducer of key metabolic enzymes, primarily Cytochrome P450 3A4 (CYP3A4), and the drug transporter P-glycoprotein (P-gp). This induction leads to a formally documented reduction in the plasma concentrations and systemic exposure of many co-administered substances.

Regulatory authorities mandate that several combinations are contraindicated. This includes immunosuppressants, such as Cyclosporine and Tacrolimus, where reduced exposure risks loss of efficacy and allograft rejection. Antiretrovirals, certain oral anticoagulants (like Warfarin), and hormonal contraceptives also face a documented risk of treatment failure due to lowered blood levels.


A separate interaction is classified as pharmacodynamic, concerning the product’s additive effect with other serotonergic agents. Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs), Monoamine Oxidase Inhibitors (MAOIs), or Triptans is strictly prohibited due to the elevated, officially acknowledged risk of developing serotonin syndrome. Furthermore, official prescribing information recommends discontinuation of the product at least two weeks before scheduled surgical procedures.

Mechanism of Action

The physiological action of Blackmores Hyperiforte, derived from Hypericum perforatum, is achieved through a multifactorial mechanism centered on modulating neurotransmitter availability and the stress response system.

The main mechanism, driven by the constituent hyperforin, involves the functional inhibition of presynaptic neurotransmitter reuptake. Hyperforin acts as an activator on the neuronal TRPC6 ion channel, which disrupts the Na^+-dependent electrochemical gradient required for reuptake transporters to clear monoamines (like serotonin and norepinephrine) from the synapse. This molecular event leads to a sustained elevation of these key monoamines, reinforcing the signaling pathways critical for neural circuits regulating emotion and homeostatic control of CNS signaling.

Beyond direct synaptic action, the extract modulates the Hypothalamic-Pituitary-Adrenal (HPA) axis, which regulates neuroendocrine feedback relating to glucocorticoids. By influencing this feedback loop, the mechanism modulates the physiological output of the HPA axis. The full development of its physiological effect relies on secondary neurobiological adaptations (such as receptor changes), which explains the necessary delayed onset for the full action to manifest.

Dosage and Administration Information

This section outlines the administration instructions for Blackmores Hyperiforte tablet, based on product documentation and public-facing instructions. Variations in instructions may occur between regions, and users should always consult the specific product labeling.

Official Administration Instructions

The following rules define the procedure for using this product:

  • Targeted User Group: This medicine is only for Adults.
  • Route of Administration: The tablet is intended for Oral consumption.
Dosing Instruction Domain Labeling Pattern A Labeling Pattern B
Standard Dose 1 tablet 1 tablet
Dosing Frequency Three times per day Once daily
Administration Timing With food 1 hour before bedtime
Duration of Use Not explicitly specified 4–6 consecutive weeks

Procedural Summary

The use protocol requires that the medicine be taken by Adults only. The dosing regimen is to take one tablet orally, with the specific frequency and timing varying by region (e.g., three times daily with food or once daily an hour before bed, as indicated in different product labeling). The use should adhere to the prescribed duration where specified, such as 4–6 consecutive weeks outlined in certain instructions.

Recent Clinical Evidence

Research Evidence: Study Landscape for Blackmores Hyperiforte

This section summarizes the structure and nature of the clinical research that was evaluated in the regulatory context for the active ingredient, St John's Wort (Hypericum perforatum) extract. These studies help show what has been observed so far in specific research settings.


Evidence for Use in Mild to Moderate Depressive Episodes

The active ingredient, St John's Wort extract, was studied for conditions characterized by fluctuating or episodic manifestations of mood distress in adult outpatients, relying primarily on Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. Researchers examined outcomes related to systemic or functional imbalance using standardized psychological tools. The findings describe patterns observed in the studies where measurements on mood scores were observed over the observation period in the studied populations.

The trials included comparisons against placebo, and research also examined the extract in comparison to other studied treatments. However, evidence quality varies across studies, with some earlier trials showing lower methodological scores. Long-term effects are not fully established for this indication; most trials are limited to short-term observation periods (4 to 12 weeks).

Evidence for Use in Symptoms of Nervous Tension and Restlessness

The extract was also studied in research contexts involving fluctuating or unstable symptoms for emotional instability, including symptoms like nervous tension and inner restlessness. Research in this area is largely derived from secondary analysis of the larger mood trials, focusing on outcomes related to episodic or acute changes.

Studies reported measurements related to anxiety components and subjective restlessness. However, subgroup findings are uncertain when isolating these specific symptoms, as they are rarely the single, primary outcome of a trial. The reliance on outcomes derived from mood scales means that the targeted data for studying nervous tension as a sole complaint is limited.

What is Still Uncertain About the Research Evidence

The primary area of uncertainty involves the methodological heterogeneity of the evidence base. The specific preparation of Hypericum perforatum extract used varied widely across international trials, and this variation was associated with inconsistent outcomes across the research. Additionally, comparative evidence is lacking for certain specific formulations against all contemporary pharmaceutical treatments. The evidence highlights what is known — and what is still uncertain—regarding standardization and the applicability of results across different extract types.

Key Studies & References

  1. St. John's Wort and Depression: In Depth (National Center for Complementary and Integrative Health - NCCIH)
  2. NATURAL HEALTH PRODUCT ST. JOHN'S WORT – HYPERICUM PERFORATUM Oral Monograph (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Blackmores Hyperiforte (FAQ)


Q: How quickly does Blackmores Hyperiforte usually start working?

Regulatory assessments for the active ingredient often rely on evidence from clinical trials where observable changes in mood or symptoms were typically evaluated over observation periods ranging from 4 to 12 weeks. The full development of its physiological effect is described as relying on secondary neurobiological adaptations that may require time to manifest.


Q: What is the typical timeframe before the full effects of Blackmores Hyperiforte are felt?

The full development of the physiological effect is described as relying on secondary neurobiological adaptations within the nervous system. For this reason, the established timeframe for observing the maximum benefit in clinical trials is generally 4 to 12 weeks.


Q: Can Blackmores Hyperiforte cause sensitivity to sunlight?

Official safety constraints state that preparations containing this active ingredient are formally associated with a risk of photosensitivity. This means there is a potential for intensified sunburn-like symptoms (phototoxicity), particularly when exposed to strong sunlight or UV irradiation.


Q: Are there any common side effects people report with Blackmores Hyperiforte besides skin reactions?

Adverse effects reported with the active ingredient include effects on the gastrointestinal system (e.g., digestive discomfort, nausea, diarrhea), the nervous system (e.g., dizziness or headaches), and psychiatric changes (e.g., restlessness or anxiety).


Q: Why are people often told to check with a doctor before combining Blackmores Hyperiforte with other medications?

Regulatory documents describe the rationale for this precaution by highlighting two primary risks. Firstly, the product can significantly reduce the concentration of many co-administered prescription medicines, risking therapeutic failure. Secondly, combining it with other serotonergic agents can greatly increase the risk of serious side effects like serotonin syndrome.


Q: If I stop taking Blackmores Hyperiforte, will there be withdrawal effects?

Some regulatory sources advise against abrupt discontinuation of the preparation, citing the potential for withdrawal-like symptoms, while others indicate a gradual taper may not be required. Any change to the use protocol is often approached with caution.


Q: What is the difference between Blackmores Hyperiforte and other St John's Wort supplements?

Official documents note that preparations containing St John's Wort are often not subject to the same strict regulation as prescription medicines. Therefore, the potency and concentrations of active ingredients may vary significantly between different supplements.


Q: Is Blackmores Hyperiforte known to affect sleep patterns?

Insomnia (difficulty sleeping) and vivid dreams are adverse effects that have been reported with the use of the active ingredient. Users should be aware that their sleep patterns may be affected.


Q: Does Blackmores Hyperiforte have any known food interactions, like with grapefruit?

Regulatory warnings indicate that consumption of alcohol should be avoided or limited, as it may increase nervous system side effects. Additionally, specific tyramine-rich foods, such as aged cheeses and certain wines, may interact due to possible effects on blood pressure.


Q: Are there specific groups of people who should avoid Blackmores Hyperiforte, even if healthy?

Official documents list populations with safety constraints, even if not currently unwell. This notably includes women who are pregnant or breastfeeding, as safety data is considered insufficient to establish safe use for the fetus or infant.


Q: Has Blackmores Hyperiforte been studied in teenagers or younger adults?

Use is generally not recommended in children and adolescents under 18 years of age because data are insufficient to establish the safety and efficacy of the preparation in this younger age group, leading to a constraint on use.


Q: Is Blackmores Hyperiforte considered safe to take while driving or operating machinery?

The active ingredient can cause central nervous system effects such as dizziness or difficulty concentrating (drowsiness). Users should be aware that these adverse effects may affect their ability to safely drive or operate heavy machinery.


Q: Can Blackmores Hyperiforte cause digestive upset or stomach issues?

Adverse effects reported with the active ingredient include gastrointestinal discomfort, nausea, and diarrhea. These effects are among the adverse reactions reported across preparations containing this botanical extract.


Q: Does Blackmores Hyperiforte contain any common allergens like lactose or nuts?

According to the official product warnings and labeling for Blackmores Hyperiforte, the preparation contains soya (soybeans). The full ingredient list provides comprehensive details on all components.


Q: Can men and women use Blackmores Hyperiforte for the same purposes?

The established regulatory indications for the active ingredient relate to mood balance and nervous tension and are not constrained by gender. The primary safety constraints are focused on age, pre-existing conditions, and women who are pregnant or breastfeeding.


Q: What are the general expectations for benefits when using Blackmores Hyperiforte?

Regulatory evaluation relies on research that has examined the active ingredient's effectiveness against some standard treatments for mild to moderate low mood. Findings describe that the extract is often associated with fewer reported adverse reactions.


Q: Do researchers know exactly which component of St John's Wort causes the effects of Blackmores Hyperiforte?

Pharmacological studies have identified hypericin and hyperforin as active constituents believed to contribute to the effects. However, the final action on the nervous system is believed to be multifactorial, involving the combined influence of several compounds within the standardized extract.


Q: Is Blackmores Hyperiforte meant to be taken with food or on an empty stomach?

Official administration instructions regarding food vary depending on regional regulation. Some authorities advise taking the tablet with food, while others recommend taking it 1 hour before bedtime (on an empty stomach). It is important to adhere to the specific directions on the product label for the relevant region.


Q: Are there any documented cases of interactions between Blackmores Hyperiforte and alcohol?

Regulatory sources caution users to avoid or limit the use of alcohol, as it may increase nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.


Q: Does Blackmores Hyperiforte interact with medications used for high blood pressure?

The active ingredient is known to reduce the blood levels of various medicines metabolized by the liver, and this interaction may affect the effectiveness of some types of blood pressure medicines (antihypertensives).


Q: Do official documents mention specific mental health conditions that Blackmores Hyperiforte is used for?

Official regulatory indications and literature primarily define its use for treating symptoms of mild to moderate depressive episodes and associated nervous tension and restlessness.

How should Blackmores Hyperiforte be stored and disposed of?

The storage and disposal of Blackmores Hyperiforte must follow the specific instructions set by regulatory authorities to preserve the medicine's stability and ensure environmental safety.

️ Storage and Protection Requirements

Storage Condition Requirement (Official Labeling)
Temperature Store below 30 C
Environmental Protect from light and moisture; keep in a dry place
Packaging Must be kept in the original container
Child Safety Store out of the sight and reach of children

️ Disposal Instructions

Expired or unused tablets must not be disposed of in household waste or flushed down the toilet (wastewater). Disposal must adhere to local regulations, which generally requires returning the product to a pharmacist or designated collection point to safeguard the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blackmores Hyperiforte found in:

A-Z Index: